A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Status:
Not yet recruiting
Trial end date:
2025-03-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of nipocalimab on total serum
immunoglobulin G (IgG) in pediatric participants 2 to less than (<) 18 years of age, the
safety and tolerability of treatment with nipocalimab in children and adolescents and to
evaluate the pharmacokinetics (PK) of nipocalimab in children and adolescents with
generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing,
stable standard-of-care therapy.